Atopic Dermatitis and Food Triggers
Could certain foods trigger the red, itchy skin flares of atopic dermatitis? It’s possible for foods like milk, wheat, shellfish, peanuts, or soy to set off irritating skin rashes, but they aren’t always the culprit. Find out how your doctor can test you to see if your diet is linked to skin flares and suggest treatments. (Source: WebMD Health)
Source: WebMD Health - February 8, 2024 Category: Consumer Health News Source Type: news
Atopic Dermatitis: How to Get Enough Sleep
The itchy rashes that come with atopic dermatitis (AD) can keep you awake. Find out how to dull the itch and get your rest. (Source: WebMD Health)
Source: WebMD Health - February 8, 2024 Category: Consumer Health News Source Type: news
Atopic Dermatitis: Help for Broken Skin
Living with atopic dermatitis often means living with itchy rashes and cracked, broken skin. Learn how to care for your skin and prevent further damage. (Source: WebMD Health)
Source: WebMD Health - February 8, 2024 Category: Consumer Health News Source Type: news
Dupilumab Improves AD Affecting the Hands, Feet Dupilumab Improves AD Affecting the Hands, Feet
Dupilumab monotherapy was an effective and safe systemic treatment for patients with moderate to severe hand and foot atopic dermatitis.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - February 6, 2024 Category: Pediatrics Tags: Dermatology Source Type: news
Glenmark partners with Pfizer to launch abrocitinib in India to treat atopic dermatitis
Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO). It is also approved by the USFDA, European Medicines Agency (EMA), and other regulatory agencies. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 31, 2024 Category: Pharmaceuticals Source Type: news
What is the Differential Diagnosis of Normal Eye Crusts or Rheum?
Discussion
Sleep crusts go by lots of names including “sleepies,” “sleepers,” “eye goop,” “eye sand,” and many other names. Rheum is the medical term. Sleep crusts are common. The sandman from folklore, is said to sprinkle magical sand into people’s eyes to encourage sleep and wonderful dreams.
Crusts are composed of mucous, oil, skin cells, and dust/debris that is all a normal part of normal tear production and protection of the eye. While awake, blinking helps to clear this from the eye and move it to the nasolacrimal duct. This does not occur during sleep and there...
Source: PediatricEducation.org - January 29, 2024 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Proper Dermatology Diagnoses Crucial for Accurate Treatment Proper Dermatology Diagnoses Crucial for Accurate Treatment
Many types of dermatitis look the same but act differently, dermatologists said, encouraging primary care clinicians to seek assistance via traditional referrals or telemedicine.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 26, 2024 Category: Allergy & Immunology Tags: Family Medicine/Primary Care Source Type: news
Climatic Hazards Linked to Aggravation of Atopic Dermatitis
WEDNESDAY, Jan. 24, 2024 -- Climatic hazards are likely to aggravate atopic dermatitis (AD), with the impact including direct and indirect effects, according to a review published online Jan. 24 in Allergy.
Sheng-Pei Wang, M.D., M.P.H., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 24, 2024 Category: Pharmaceuticals Source Type: news
Diet and Skin: What is the Evidence? Diet and Skin: What is the Evidence?
There are scientific studies linking dietary factors to acne, atopic dermatitis, rosacea, and other common skin conditions.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 22, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Study IDs Risks to Offspring Associated With Prenatal Opioid Exposure
FRIDAY, Jan. 19, 2024 -- Prenatal opioid exposure (POE) is associated with an increased risk for infection, eczema and dermatitis, and asthma in offspring, but it is not linked to allergies or anaphylaxis, according to a study published online Jan.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 20, 2024 Category: Pharmaceuticals Source Type: news
Opioid Exposure in Womb Tied to Kids' Risk for Eczema, Dermatitis, and Asthma
(MedPage Today) -- Opioid use during pregnancy for pain or opioid use disorder (OUD) was associated with an increased risk for hospitalizations and emergency department (ED) visits for immune-related conditions in exposed offspring, a retrospective... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - January 18, 2024 Category: Psychiatry Source Type: news
New Molecules Reflect Advances in Atopic Dermatitis New Molecules Reflect Advances in Atopic Dermatitis
Topical formulations of JAK inhibitors could help treat moderate to severe atopic dermatitis in adults and adolescents, said one dermatologist.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2024 Category: Consumer Health News Tags: Dermatology Source Type: news
Dupixent (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent® (dupilumab) in atopic... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 16, 2024 Category: Drugs & Pharmacology Source Type: news
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (eczema). The trial met the primary efficacy endpoint, the percent change from…#eczema #eczemaarea #bid #oncedaily #williamblair (Source: Reuters: Health)
Source: Reuters: Health - January 10, 2024 Category: Consumer Health News Source Type: news
5-Year Safety Data From Upadacitinib Trials Reported 5-Year Safety Data From Upadacitinib Trials Reported
Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - January 3, 2024 Category: Dermatology Tags: Dermatology Source Type: news
